JP7824282B2 - 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用 - Google Patents

縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用

Info

Publication number
JP7824282B2
JP7824282B2 JP2023519291A JP2023519291A JP7824282B2 JP 7824282 B2 JP7824282 B2 JP 7824282B2 JP 2023519291 A JP2023519291 A JP 2023519291A JP 2023519291 A JP2023519291 A JP 2023519291A JP 7824282 B2 JP7824282 B2 JP 7824282B2
Authority
JP
Japan
Prior art keywords
group
optionally substituted
alkyl
substituents selected
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023519291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543038A5 (enExample
JP2023543038A (ja
Inventor
伸之 松永
淳也 白井
友洋 大川
泰史 宮本
善右 塩川
崇 中畑
章人 渋谷
彰 河田
マッコス，マルコム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardurion Pharmaceuticals Inc
Original Assignee
Cardurion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardurion Pharmaceuticals Inc filed Critical Cardurion Pharmaceuticals Inc
Publication of JP2023543038A publication Critical patent/JP2023543038A/ja
Publication of JP2023543038A5 publication Critical patent/JP2023543038A5/ja
Application granted granted Critical
Publication of JP7824282B2 publication Critical patent/JP7824282B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2023519291A 2020-09-28 2021-09-24 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用 Active JP7824282B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063084217P 2020-09-28 2020-09-28
US63/084,217 2020-09-28
PCT/US2021/052025 WO2022067082A1 (en) 2020-09-28 2021-09-24 Fused heteroaryl compounds and their use as camkii inhibitors

Publications (3)

Publication Number Publication Date
JP2023543038A JP2023543038A (ja) 2023-10-12
JP2023543038A5 JP2023543038A5 (enExample) 2024-10-01
JP7824282B2 true JP7824282B2 (ja) 2026-03-04

Family

ID=80821052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519291A Active JP7824282B2 (ja) 2020-09-28 2021-09-24 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用

Country Status (14)

Country Link
US (2) US11795172B2 (enExample)
EP (1) EP4216948A4 (enExample)
JP (1) JP7824282B2 (enExample)
KR (1) KR20230107551A (enExample)
CN (1) CN116940354A (enExample)
AU (1) AU2021350015A1 (enExample)
CA (1) CA3196946A1 (enExample)
CL (1) CL2023000894A1 (enExample)
CO (1) CO2023005189A2 (enExample)
IL (1) IL301480A (enExample)
MX (1) MX2023003610A (enExample)
PE (1) PE20240148A1 (enExample)
TW (1) TW202229273A (enExample)
WO (1) WO2022067082A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7824282B2 (ja) * 2020-09-28 2026-03-04 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用
WO2023134692A1 (zh) * 2022-01-13 2023-07-20 浙江同源康医药股份有限公司 多环类化合物及其用途
CN115160235B (zh) * 2022-08-10 2023-12-15 宜宾学院 一种2,3-二氢喹唑啉-4(1h)-酮类化合物及其超声合成方法
US20250145630A1 (en) * 2023-11-07 2025-05-08 Cardurion Pharmaceuticals, Inc. Polymorphs of a pyridinylimidazo[1,2-b]pyridazine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505000A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
US20180148457A1 (en) 2016-11-30 2018-05-31 Gilead Sciences, Inc. Fused heterocyclic compounds as cam kinase inhibitors
WO2020068854A1 (en) 2018-09-25 2020-04-02 Cardurion Pharmaceuticals, Llc Aminopyrimidine compound

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1317266A2 (en) 2000-08-08 2003-06-11 Ortho-McNeil Pharmaceutical, Inc. Neuroprotective 2-pyridinamine compositions and related methods
HK1054393B (en) 2000-09-20 2009-08-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
JP2007504229A (ja) 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類
US7776857B2 (en) 2007-04-05 2010-08-17 Amgen Inc. Aurora kinase modulators and method of use
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
HRP20180037T1 (hr) 2012-04-17 2018-03-23 Fujifilm Corporation Heterociklični spoj koji sadrži dušik ili njegovu sol
CN107074856A (zh) * 2014-09-05 2017-08-18 阿略斯泰罗斯医疗公司 CaMKII抑制剂及其用途
CN110799190B (zh) 2017-03-27 2024-04-19 卡都瑞恩医药有限公司 杂环化合物
WO2020068846A1 (en) * 2018-09-25 2020-04-02 Heterocyclic Compound Heterocyclic compound
US20230000842A1 (en) 2019-01-17 2023-01-05 Samumed, Llc Methods of treating cartilage disorders through inhibition of clk and dyrk
JP7824282B2 (ja) * 2020-09-28 2026-03-04 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505000A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
US20180148457A1 (en) 2016-11-30 2018-05-31 Gilead Sciences, Inc. Fused heterocyclic compounds as cam kinase inhibitors
WO2020068854A1 (en) 2018-09-25 2020-04-02 Cardurion Pharmaceuticals, Llc Aminopyrimidine compound

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
O’HANLON, Ryan et al.，"An Influenza Virus Entry Inhibitor Targets Class II PI3 Kinase and Synergizes with Oseltamivir"，ACS Infectious Diseases，2019年08月26日，Vol. 5，No. 10，p.1779-1793，DOI: 10.1021/acsinfecdis.9b00230
STN REGISTRY file，2019年06月12日， [Online], retrieved on 07 JUL 2025
WOODS, Keith W. et al.，"Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors"，Bioorganic & Medicinal Chemistry，2006年10月，Vol. 14，No. 20，p.6832-6846，DOI: 10.1016/j.bmc.2006.06.047

Also Published As

Publication number Publication date
AU2021350015A1 (en) 2023-06-08
EP4216948A1 (en) 2023-08-02
CN116940354A (zh) 2023-10-24
IL301480A (en) 2023-05-01
US12528816B2 (en) 2026-01-20
US20220098207A1 (en) 2022-03-31
JP2023543038A (ja) 2023-10-12
CL2023000894A1 (es) 2023-09-15
PE20240148A1 (es) 2024-02-06
AU2021350015A9 (en) 2024-10-03
MX2023003610A (es) 2023-07-20
TW202229273A (zh) 2022-08-01
CA3196946A1 (en) 2022-03-31
WO2022067082A1 (en) 2022-03-31
CO2023005189A2 (es) 2023-08-09
US20240182474A1 (en) 2024-06-06
KR20230107551A (ko) 2023-07-17
US11795172B2 (en) 2023-10-24
EP4216948A4 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
KR102638678B1 (ko) 헤테로시클릭 화합물
JP7824282B2 (ja) 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用
KR102403287B1 (ko) 헤테로고리 화합물
ES2708211T3 (es) 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas
AU2012320582A1 (en) Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
EA026385B1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
ES2927529T3 (es) Compuesto heterocíclico condensado
US20230117295A1 (en) Nitrogen containing heterocycles as cdk12 inhibitors
WO2022023340A1 (en) Substituted heterocyclic compounds and therapeutic uses thereof
CA3116141C (en) Cycloalkane-1,3-diamine derivative
JP6706250B2 (ja) 複素環化合物
KR102946104B1 (ko) 아미노피리미딘 화합물
EA052559B1 (ru) Конденсированные гетероарильные соединения и их применение в качестве ингибиторов camkii
EP3514149B1 (en) Heterocyclic amide compound
NZ728416B2 (en) 2-(morpholin-4-yl)-1,7-naphthyridines
NZ623098B2 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240920

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260219

R150 Certificate of patent or registration of utility model

Ref document number: 7824282

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150